^
4ms
New P2 trial
|
177Lu-LNC1004
9ms
Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. (PubMed, Signal Transduct Target Ther)
This was emphasized by the observed increase in antigen processing and presentation juxtaposed with T cell inactivation. In conclusion, our data supported the efficacy of immunotherapy combined with 177Lu-LNC1004 for cancer patients with FAP-positive tumors.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CD8 (cluster of differentiation 8) • FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
over1year
New P1 trial • Metastases
|
177Lu-LNC1004
2years
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Yantai LNC Biotechnology Singapore PTE. LTD.
New P1 trial
|
FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004